Birthe Lund
Birthe Lund
associate professor Aalborg University
Verified email at learning.aau.dk
Title
Cited by
Cited by
Year
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
JP Neijt, SA Engelholm, MK Tuxen, PG Sørensen, M Hansen, C Sessa, ...
Journal of Clinical Oncology 18 (17), 3084-3092, 2000
5292000
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
H Anderson, B Lund, F Bach, N Thatcher, J Walling, HH Hansen
Journal of Clinical Oncology 12 (9), 1821-1826, 1994
4771994
Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
B Lund, OP Hansen, K Theilade, M Hansen, JP Neijt
JNCI: Journal of the National Cancer Institute 86 (20), 1530-1533, 1994
4021994
Topoisomerase I inhibitors: topotecan and irenotecan
GJ Creemers, B Lund, J Verweij
Cancer treatment reviews 20 (1), 73-96, 1994
2911994
Clinical and preclinical activity of 2′, 2′-difluorodeoxycytidine (gemcitabine)
B Lund, PEG Kristjansen, HH Hansen
Cancer treatment reviews 19 (1), 45-55, 1993
1561993
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
J Verweij, B Lund, J Beijnen, A Planting, M de Boer-Dennert, I Koier, ...
Annals of oncology 4 (8), 673-678, 1993
1451993
Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
L Sengeløv, C Kamby, B Lund, SA Engelholm
Journal of clinical oncology 16 (10), 3392-3397, 1998
1001998
High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
B Lund, M Hansen, OP Hansen, HH Hansen
Journal of Clinical Oncology 7 (10), 1469-1473, 1989
761989
Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
B Lund, OP Hansen, JP Neijt, K Theilade, M Hansen
Anti-Cancer Drugs 6, 61-62, 1995
671995
Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy.
B Lund, M Hansen, F Lundvall, NC Nielsen, BL Sørensen, HH Hansen
Surgery, gynecology & obstetrics 169 (3), 213-218, 1989
631989
Phase I Study of Single, Escalating Doses of a Superantigen—Antibody Fusion Protein (PNU-214565) in Patients With Advanced Colorectal or Pancreatic Carcinoma
SE Nielsen, J Zeuthen, B Lund, B Persson, J Alenfall, HH Hansen
Journal of Immunotherapy 23 (1), 146-153, 2000
542000
Correlation of abdominal ultrasound and computed tomography scans with second-or third-look laparotomy in patients with ovarian carcinoma
B Lund, K Jacobsen, L Rasch, F Jensen, K Olesen, K Feldt-Rasmussen
Gynecologic oncology 37 (2), 279-283, 1990
521990
Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications
B Lund, HK Thomsen, J Olsen
Apmis 99 (1‐6), 353-358, 1991
471991
Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
B Lund, M Hansen, OP Hansen, HH Hansen
Journal of Clinical Oncology 8 (7), 1226-1230, 1990
441990
Gemcitabine in cisplatin-resistant ovarian cancer.
B Lund, JP Neijt
Seminars in oncology 23 (5 Suppl 10), 72-76, 1996
431996
Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma
B Lund, P Williamson, HC van Houwelingen, JP Neijt
Cancer research 50 (15), 4626-4629, 1990
361990
Phase II study of gemcitabine (2', 2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer
B Lund, M Ryberg, P Meidahl Petersen, H Anderson, N Thatcher
Annals of oncology 5 (9), 852-853, 1994
351994
Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma.
B Lund, P Williamson
Obstetrics and gynecology 76 (4), 617-622, 1990
351990
The role of second-look laparotomy in the long-term survival in ovarian cancer
MK Tuxen, G Strauss, B Lund, M Hansen
Annals of oncology 8 (7), 643-648, 1997
321997
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
JP Neijt, SA Engelholm, PO Witteveen, MK Tuxen, PG Sørensen, ...
Seminars in oncology 24 (5 Suppl 15), S15-36, 1997
311997
The system can't perform the operation now. Try again later.
Articles 1–20